Aakash Desai, Associate Professor at UAB O’Neal Cancer Center, shared on X:
“My 2022 JAMA Oncology essay ‘Avoiding Checkmate’, seems relevant for thinking about EGFR lung cancer.
Post-osimertinib EGFRm NSCLC:
- Ami-chemo approved (MARIPOSA-2)
- Dato-DXd (AA)
- Ivonescimab, OS missed.
How do we plan line 3 at diagnosis?”
Title: Avoiding Checkmate – Playing Chess With Cancer
Author: Aakash Desai
You can also read:
